secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001447362-22-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences FY2021 revenue $94.1M (+50% YoY); guides FY2022 $115-120M
----------------------------------------------------------------------------

- Full-year 2021 revenue $94.1M, up 50% vs $62.6M in 2020; net loss $(31.3)M vs $(10.3)M.
- Total GEP test volume 28,118 (+55% YoY); DecisionDx-Melanoma 20,328 (+25%).
- Q4 revenue $25.0M (+45% YoY); delivered 8,242 test reports (+60%).
- Cash and equivalents $330M at Dec. 31, 2021; adjusted EBITDA $(14.9)M for 2021.
- FY2022 revenue expected $115-120M; includes TissueCypher Barrett's esophagus test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000043/0001447362-22-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000043/cstl-20220228.htm
  HTML page:      https://secwatch.observer/filing/0001447362-22-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer